ÂÜÀòÂÒÂ×

John joined Nuvalent in January 2020 and leads the strategy and execution of translational development activities of the company’s lead programs, including ADME, nonclinical safety and clinical pharmacology.

John began his career at Pfizer in Groton, CT. While at Pfizer, John developed a novel in vitro ADME/safety assay which was used by the company globally to help reduce drug safety risk. In addition to his research, John was a member of the Pfizer hepatotoxicity working group and global hepatotoxicity reduction initiative. In 2005, John was awarded the Pfizer Global Research and Development Achievement Award for his impact, cross functional collaboration and contributions to the company. John then moved to GlaxoSmithKline in North Carolina to become Chief Scientist in the infectious diseases center of emphasis for drug discovery (CEDD). In this role, John served as a senior DMPK project leader, group supervisor and prepared ADME/PK packages for IND submission. At GSK, John was also a member of the global drug induced liver injury (DILI) taskforce, leveraging his experience to reduce drug attrition due to hepatotoxicity. Following his time in pharma, John joined Infinity Pharmaceuticals as head of DMPK in 2012. While at Infinity, John was the DMPK lead on the duvelisib Product Development Team, responsible for preparing the ADME/PK package for NDA submission. John was also the eganelisib (IPI-549) Product Development Team leader, successfully leading the cross-functional team to IND submission and into early clinical development. Most recently John was at Decibel Therapeutics where, in addition to leading the DMPK, clinical pharmacology and regulated bioanalytical functions, he was the early Product Development Scientific Lead on the DB-020 program which is currently in clinical trials for the prevention of chemotherapy induced hearing loss.

John earned his PhD in Chemistry from Northeastern University.